Corindus Vascular Robotics, Inc. (NYSE:CVRS) produced a 67.12% rally since recording the worst price of $0.7. Thanks to the latest -1.68% decrease, it now trades at $1.17. Throughout the trading on 01/17/2019, the share price floated between $1.16 and $1.25. This company shares are 55.56% off its target price of $1.82 and the current market capitalization stands at $223.86M. The recent change has given its price a 2.43% lead over SMA 50 and -29.09% deficit over its 52-week high. The stock witnessed 3.54% gains, -13.97% declines and 15.84% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CVRS’s volatility during a week at 7.04% and during a month it has been found around 9.96%.Corindus Vascular Robotics, Inc. (CVRS) Top Holders
Institutional investors currently hold around $73 million or 48.9% in CVRS stock. Look at its top three institutional owners. Healthcor Management, L.P. owns $23.78 million in Corindus Vascular Robotics, Inc., which represents roughly 10.62% of the company’s market cap and approximately 32.57% of the institutional ownership. Similar statistics are true for the second largest owner, Hudson Executive Capital Lp, which owns 11,336,154 shares of the stock are valued at $13.49 million. The third largest holder is Millennium Management Llc, which currently holds $8.35 million worth of this stock and that ownership represents nearly 3.73% of its market capitalization.Corindus Vascular Robotics, Inc. 13F Filings
At the end of September reporting period, 18 institutional holders increased their position in Corindus Vascular Robotics, Inc. (NYSE:CVRS) by some 9,236,764 shares, 25 decreased positions by 3,222,295 and 17 held positions by 48,629,042. That puts total institutional holdings at 61,088,101 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 5,642,052 shares while 11 institutional investors sold out their entire positions totaling 1,329,091 shares.Corindus Vascular Robotics, Inc. (NYSE:CVRS) Insider Trades
Multiple company employees have indulged in significant insider trading. Corindus Vascular Robotics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Cannon Louis A has acquired 30,000 shares of Corindus Vascular Robotics, Inc. (CVRS) in trading session dated Aug. 24, 2018. These shares are worth $30,600 and were traded at $1.02 each. The SEC filing shows that Cannon Louis A performed a purchase of 30,000 shares. The Director added these shares by way of transaction on Aug. 22, 2018. The company’s shares were assimilated at $0.99 per share worth to an investment of some $29,700 on account of Cannon Louis A.
Director, Cannon Louis A, purchased 31,000 common shares of Corindus Vascular Robotics, Inc. (CVRS) in the open market. In a transaction dated Aug. 13, 2018, the shares were bought at an average price of $0.96, giving away a sum of $29,760. After this purchase, 7,736,345 common shares of CVRS are directly owned by the insider, with total stake valued at $9,051,524.
In the transaction dated May. 25, 2018, the great number of shares acquired came courtesy the Director; Cannon Louis A added a total of 16,500 shares at an average price of $0.79, amounting to approximately $13,035. The insider now directly owns 7,646,891 shares worth $8,946,863.Corindus Vascular Robotics, Inc. (CVRS) Analyst Guide
Several analysts have released their opinion on Corindus Vascular Robotics, Inc. (NYSE:CVRS), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.